Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Ophthalmic Res ; 2022 Aug 23.
Artículo en Inglés | MEDLINE | ID: mdl-35998587

RESUMEN

PURPOSE: This meta-analysis aimed to evaluate retinal vessel density (VD) in amblyopic patients using optical coherence tomography angiography (OCTA). METHODS: PubMed, Web of Science, Embase, and Cochrane Library databases were systematically searched for published articles comparing retinal microvasculature characteristics in patients with amblyopia and controls. Continuous variable outcomes were assessed using the mean difference (MD) with a 95% confidence interval. Review Manager Version 5.30 was used for the analysis. RESULTS: Thirteen qualified articles were pooled in this meta-analysis. Compared with controls, the foveal whole enface VD of superficial (SCP) and deep capillary plexus (DCP) of patients as measured by 3×3-mm scans were significantly lower in amblyopia eyes (MD: -1.37, P = 0.0003; MD: 1.70, P < 0.00001, respectively). Similarly, in the 6×6-mm scans, foveal whole enface VD of the SCP and DCP were remarkably lower in amblyopia eyes than in controls (MD: -2.24, P = 0.03; MD: -5.08, P = 0.04, respectively). The parafoveal VD of SCP in 3×3-mm scans (MD: -1.96, P < 0.00001) was also lower in amblyopic patients than in controls. Similarly, in 6×6-mm scans, amblyopia eyes showed a significant decrease, and a trending decrease in the parafoveal VD of the SCP (MD: -3.85, P = 0.007) and DCP (MD: -3.03, P = 0.10), respectively. For whole radial peripapillary capillary (RPC), VD was significantly reduced in amblyopic patients compared to controls (MD = -0.83, P < 0.00001). In addition, the deep foveal avascular zone (FAZ) was larger in amblyopic eyes than in the controls (MD = 0.55, P= 0.007). CONCLUSIONS: Our data suggest that whole foveal and parafoveal VD and RPC whole VD were reduced in patients with amblyopia. Moreover, our results reveal that the FAZ is larger in amblyopic patients. Consequently, OCTA may have the potential for diagnosing and monitoring patients with amblyopia.

2.
Neurosci Lett ; 826: 137712, 2024 Mar 15.
Artículo en Inglés | MEDLINE | ID: mdl-38447888

RESUMEN

Glaucoma is a kind of neurodegenerative disorder characterized by irreversible loss of retinal ganglion cells (RGCs) and permanent visual impairment. It is reported that resveratrol (RES) is a promising drug for neurodegenerative diseases. However, the detailed molecular mechanisms underlying its protective potential have not yet been fully elucidated. The present study sought to investigate whether resveratrol could protect RGCs and retinal function triggered by acute ocular hypertension injury through the SIRT1/NF-κB pathway. An experimental glaucoma model was generated in C57BL/6J mice. Resveratrol was intraperitoneally injected for 5 days. Sirtinol was injected intravitreally on the day of retinal AOH injury. RGC survival was determined using immunostaining. TUNEL staining was conducted to evaluate retinal cell apoptosis. ERG was used to evaluate visual function. The proteins Brn3a, SIRT1, NF-κB, IL-6, Bax, Bcl2, and Cleaved Caspase3 were determined using western blot. The expression and localisation of SIRT1 and NF-κB in the retina were detected by immunofluorescence. Our data indicated that resveratrol treatment significantly increased Brn3a-labelled RGCs and reduced RGC apoptosis caused by AOH injury. Resveratrol administration also remarkably decreased NF-κB, IL-6, Bax, and Cleaved Caspase3 proteins and increased SIRT1 and Bcl2 proteins. Furthermore, resveratrol treatment obviously inhibited the reduction in ERG caused by AOH injury. Importantly, simultaneous administration of resveratrol and sirtinol abrogated the protective effect of resveratrol, decreased NF-κB protein expression, and increased SIRT1 protein levels. These results suggest that resveratrol administration significantly mitigates retinal AOH-induced RGCs loss and retinal dysfunction, and that this neuroprotective effect is partially regulated through the SIRT1/NF-κB pathway.


Asunto(s)
Benzamidas , Glaucoma , Naftoles , Hipertensión Ocular , Ratones , Animales , Resveratrol/farmacología , Resveratrol/uso terapéutico , FN-kappa B/metabolismo , Sirtuina 1/metabolismo , Proteína X Asociada a bcl-2 , Interleucina-6 , Ratones Endogámicos C57BL , Hipertensión Ocular/tratamiento farmacológico , Glaucoma/tratamiento farmacológico
3.
Sci Rep ; 12(1): 752, 2022 01 14.
Artículo en Inglés | MEDLINE | ID: mdl-35031636

RESUMEN

This meta-analysis aimed to analyze retinal microvasculature features in eyes with Behçet's disease (BD) using optical coherence tomography angiography (OCTA). Electronic databases, including PubMed, Web of Science, Embase, and Cochrane Library, were comprehensively searched for published studies comparing retinal microvasculature characteristics between eyes with BD and controls. Continuous variables were calculated using the mean difference (MD) with 95% confidence interval (CI). Review Manager software (version 5.30) was used to conduct statistical analysis. A total of 13 eligible studies involving 599 eyes with BD and 622 control eyes were included in the meta-analysis. The pooled results showed that the macular whole enface superficial and deep vessel density (VD) values measured by OCTA were significantly lower in eyes with BD than in control eyes (superficial VD: MD = - 3.05, P < 0.00001; deep VD: MD = - 4.05, P = 0.0004). The foveal superficial and deep VD values were also significantly lower in the BD group than in the control group (superficial VD: MD = - 1.50, P = 0.009; deep VD: MD = - 4.25, - = 0.03). Similarly, the analysis revealed a significant reduction in the parafoveal superficial and deep VD in eyes with BD than in control eyes (superficial VD: MD = - 3.68, P < 0.00001; deep VD: MD = - 4.95, P = 0.0007). In addition, the superficial and deep foveal avascular zones (FAZs) were significantly larger in patients with BD than in controls (superficial FAZ: MD = 0.06, P = 0.02; deep FAZ: MD = 0.12, P = 0.03). The present meta-analysis found that macular whole enface VD, foveal VD, and parafoveal VD were lower in eyes with BD, and the FAZ was larger in patients with BD. The findings suggest that OCTA can assist clinicians in diagnosing and monitoring the status of patients with BD.


Asunto(s)
Síndrome de Behçet/patología , Microvasos/patología , Vasos Retinianos/patología , Adulto , Síndrome de Behçet/complicaciones , Síndrome de Behçet/diagnóstico por imagen , Femenino , Fóvea Central/irrigación sanguínea , Humanos , Mácula Lútea/irrigación sanguínea , Edema Macular/diagnóstico por imagen , Edema Macular/etiología , Masculino , Microvasos/diagnóstico por imagen , Persona de Mediana Edad , Vasculitis Retiniana/diagnóstico por imagen , Vasculitis Retiniana/etiología , Vasos Retinianos/diagnóstico por imagen , Tomografía de Coherencia Óptica
4.
Exp Ther Med ; 15(1): 139-144, 2018 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-29399058

RESUMEN

Alkali burns of the cornea may lead to permanent visual impairment or complete blindness. In the current study, the role of microRNA 296 (miR-296) was explored in mouse corneal neovascularization induced by alkali burns. An alkali burn model in Balb/c mice was developed to study chemical corneal injuries. The expression of the miR-296 gene was measured by reverse-transcription-quantitative polymerase chain reaction. Fibroblast growth factor 23 (FGF23) protein expression was measured by western blot analysis. Possible impacted pathways were analyzed by Kyoto Encyclopedia of Genes and Genomes pathway analysis. miR-296 gene expression was examined following chemical corneal injury and it was demonstrated that different topical eye medications decreased miR-296 gene expression. miR-296 may participate in cytokine-cytokine receptor interaction pathways to influence corneal inflammatory responses. It was also revealed that FGF23 was expressed following chemical corneal injury and that different treatments with topical eye drops decreased its expression. miR-296 is a novel molecular modulator for alkali burns in the mouse cornea.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA